H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback